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Cytomegalovirus (CMV) remains the most common cause of viral intrauterine infection. The objective of 
this research was to determine the prevalence of at-risk pregnancies for congenital cytomegalovirus 
transmission in a randomly selected pregnant women and their newborns. Enzyme Link 
Immunosorbent Assay (ELISA) and real-time polymerase chain reaction (PCR) were utilized to screen 
the sera of mothers (n = 100) and consecutive umbilical cord blood samples from their newborn (n = 
100). Of the 100 mother's sera analyzed, 100 (100%) and 3 (3%) were positive for cytomegalovirus IgG 
and IgM antibodies, respectively. Of the 100 cord serum specimens analyzed, 99 (99%) and 2 (2%) were 
positive for cytomegalovirus IgG and IgM antibodies, respectively. Cytomegalovirus DNA was detected 
in 4 out of 100 (4%) cord blood samples of newborns. From four CMV DNA positive cases, Case 1 had 
no IgM in cord serum, but had IgM in mother's sera. Cases 2 and 4 were positive for IgM in both 
mother's sera and cord serum. Case 3 had no detectable CMV IgM in sera and cord serum. As many as 
66 and 100% of CMV IgM-positive women in this study also had CMV IgM and CMV DNA in their delivery 
cord blood samples, respectively suggesting an increased risk of congenital CMV infection in those 
pregnancies. A paired women sera/cord blood CMV IgM-negative was found to be positive for CMV 
DNA. The data may also suggest the utility of PCR in place of CMV IgM as a diagnostic method for 
congenital CMV infection. 
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INTRODUCTION 
 
Human cytomegalovirus (HCMV) remains the most 
common cause of viral intrauterine infection and the 
major cause of congenital defects in developed countries 
for over 20 years (Munro et al., 2005; Boppana et al., 
2001).  Involvement  of  CNS  is  the  most  common  and 
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important clinical manifestations of congenitally infected 
infants (Schleiss and Choo, 2006; Dollard et al., 2007). 
Transmission can occur during pregnancy or after birth, 
from breast milk, cord blood, saliva, urine, fomites and 
other sources (Lazzarotto et al., 2004). Some of infants 
are infected during delivery, through breast milk or 
following the transfusion of CMV-contaminated cord 
blood to a sero-negative newborn that is not protected by 
maternal antibodies. Congenital CMV infection is 
identified by viral isolation from the infant at birth or within 
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3 weeks of birth and diagnosis beyond that age may 
indicate acquired infection from exposure to virus in the 
birth canal or breast milk (Daiminger et al., 2005; Revello 
and Gerna, 2002). Cord blood is a sample of blood 
collected from the umbilical cord at the time of birth and 
may help mother to child transmission of CMV and 
causes congenital CMV infection. Classically, the gold 
standard diagnostic test for congenital CMV infection in 
cord blood has been viral isolation but the cell culture of 
CMV takes long time and expensive. Alternative 
approach, polymerase chain reaction (PCR) is especially 
promising for its high sensitivity, specificity and relative 
simplicity (Demler et al., 1998; Xu et al., 1993). 
The presence of CMV DNA in cord blood of infected 
pregnant women could be a risk marker for transmission 
of the virus to the fetus. Screening for congenital CMV 
may lead to more accurate diagnosis of infant mortality 
and newborn screening may help identify both 
asymptomatic and misdiagnosed cases of congenital 
CMV. The study determined the prevalence of at-risk 
pregnancies for congenital cytomegalovirus transmission 
in a randomly selected population by detection of 
cytomegalovirus specific antibodies (IgG and IgM) in the 
sera of the mothers and cytomegalovirus specific 
antibodies (IgG and IgM) and DNA in cord bloods from 
their newborns. 
 
 
MATERIALS AND METHODS 
 
Specimen collection and processing 
 
Two groups of specimens were included in the study: Group I 
consisted of serum specimens taken from 100 pregnant women 
who visited the Clinic of Rasoul Akram Hospital, Tehran, Iran, 
immediately after delivery in the period of April, 2010 and May, 
2011 were included in the study. Group II consisted of consecutive 
cord blood specimens (n = 100) taken from their newborn cord in 
the period of April, 2010 and May, 2011. The method of collection 
and processing of cord blood has been described (Kogler et al., 
1996). Patients gave their full informed consent at the time the 
samples were taken. Tehran University of Medical Science (TUMS) 
ethics committee approval was granted in March, 2010 to test these 
samples for the presence of congenital infections. The specimens 
were stored in the cord blood and serum bank of the Tehran 
University of Medical Science (TUMS) separately. 
 
 
Real-time polymerase chain reaction (PCR) assay 
 
Nucleic acid extractions were performed manually with a High pure 
viral nucleic acid kit (Roche, Germany), according to manufacturer’s 
instructions and stored at -20°C until use. The real-time PCR was 
carried out using SYBR Green Master Mix reagents containing 5 
units Taq polymerase, 0.01% gelatin, 0.6 µM of each primer, 200 
µM of each deoxynucleotid triphosphate, 5 µl of reaction buffer (50 
mM KC1, 10 mM tris-HCI, pH = 8.3) and 1.5 mM MgCl2. Samples 
were subjected to 1 cycle at 50°C for 2 min and at 95°C for 10 min, 
followed by 40 cycles at 95°C for 20 s, 60°C for 40 s using a 
thermal cycler (Rotor Gene 6000, Corbett Research). SYBR Green 
I fluorescence was detected and plotted using Rotor-gene 6000 
series software (Corbett Research) during the 60°C extension 
phase for each cycle. Threshold cycles and log starting quantities 
 
 
 
 
for patient samples were calculated. Forward and reverse primers 
were as follows: GTGTGGGACATAGGCCAGAG and 
GCGACATCC CCGCCTACTAC (201-bp product). Standard 
precautions were taken to avoid sample-to-sample contamination 
and PCR product carry-over. Sterile water, normal serum control 
and a negative serum (non reactive on multiple assays) were used 
as negative controls. CMV plasmid containing gpB region was used 
as positive control. 
 
 
Serological assay 
 
Paired sera and cord serum samples collected from 100 pregnant 
women and their newborn were examined for the presence of CMV 
IgG and IgM. Enzyme link immunosorbent assay (ELISA) was 
carried out using commercial ELISA kit (Third generation ELISA kit; 
RADIM, Italy). 
 
 
RESULTS 
 
Patient characteristics 
 
The median age of the 100 pregnant women was 34 
years. The age distribution of the study population was: < 
29 years with one birth; 29.1%; > 29 years with more than 
one birth; 70.9%. The male to female ratio of babies was 
1.31:1. There were no signs of primary infections during 
pregnancy in pregnant women. Their pregnancies were 
uncomplicated. All babies were delivered at term and 
were apparently healthy. They had a normal birth weight, 
height and head circumference. Thirty percent of these 
infants were born by cesarean section. All mothers and 
their children were discharged from the hospital 4 days 
after delivery. Clinical data of CMV positive patients are 
shown in Table 1. 
 
 
Cytomegalovirus polymerase chain reaction (PCR) 
and antibody assays 
 
The results of the cytomegalovirus PCR and antibodies 
tests in women sera and cord blood are presented in 
Table 2. Consecutive umbilical cord blood samples from 
newborn (n = 100) were analysed for cytomegalovirus 
DNA using real-time PCR. Cytomegalovirus DNA was 
detected in 4 out of 100 (4%) cord blood samples from 
newborns. Paired women sera and cord serum samples 
(n = 100) were analysed for IgG antibody levels against 
CMV using ELISA. Of the 100 mother's serum samples 
and 100 cord serum samples analysed, 100 (100%) and 
99 (99%) have detectable levels of CMV IgG antibodies 
respectively. Sera samples of pregnant mothers (n = 100) 
and cord serum (n = 100) were analysed for IgM antibody 
levels against CMV using ELISA. Of the 100 sera and 
100 cord serum samples analysed, 3 (3%) and 2 (2%) 
have detectable levels of CMV IgM antibodies 
respectively. In total, 4 cases had CMV IgM or CMV DNA 
identified in women sera or cord blood specimens of their 
neonates. Case 1 had no IgM in cord serum, but had IgM
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Table 1. Clinical presentation and demographics of CMV positive cases. 
 
Mothers 
 
Infants 
Pair no. Age Gestational age (week) 
Mode of 
pregnancy 
Mode of 
delivery 
Prior 
pregnancy 
Sign of 
infection Sex 
Birth 
weight (g) 
Height 
(cm) 
Head 
circumference 
Sign of 
infection 
1 33 38 Uncomplicated Spontaneous 1  None Male 2900 50 33 None 
2 35 38 Uncomplicated Spontaneous 1  None Female 3200 55 35 None 
3 27 38 Uncomplicated Caesarean 0  None Female 3000 49 35 None 
4 29 40 Uncomplicated Spontaneous 0  None Male 3300 52 36 None 
 
 
 
Table 2. Comparison of the ELISA and PCR results for CMV positive patients. 
 
Mothers 
 
Infants 
Pair no. Sera IgG Sera IgM Cord serum IgG Cord blood IgM Cord blood PCR 
1 + +  + - + 
2 + +  + + + 
3 + -  + - + 
4 + +  + + + 
 
 
 
in sera and CMV DNA in cord blood. Cases 2 and 
4 were identified as positive for IgM in both sera 
and cord serum and CMV DNA in cord blood. 
Case 3 had no detectable CMV IgM in sera and 
cord serum; however she had CMV DNA in cord 
blood. 
 
 
DISCUSSION 
 
The seroprevalence of CMV varies according to 
studies conducted in different parts of the world. 
But, it has been reported that 0.2 to 2% of live 
birth have congenital CMV infection, considering 
as the leading cause of congenital infections 
worldwide (Demmler, 1991; Brown and 
Abernathy, 1998; Kumar et al., 1973). The fetus is 
at risk of acquiring CMV infection either 
intrauterine or delivery. Intrauterine transmission 
of CMV infection may occur following either 
primary or recurrent infection (Ahlfors et al., 1988; 
Fowler et al., 1992). Involvement of central 
nervous system (CNS), including late central 
nervous system sequelate, primarily sensory-
neuronal deafness is the most important clinical 
manifestation in 10 to 20% of such CMV 
congenital infected infants. Screening of mothers 
for CMV and early diagnosis play an important 
role to minimize CMV congenital infection and its 
serious consequences. 
Molecular and serological assays were utilized 
to screen CMV congenital infection in pregnant 
women sera and cord blood of their newborns at 
the time of delivery and analyzed the distribution 
of CMV infection in a group of population with no 
history of CMV infection. The study showed a 
frequency of 4% for CMV infection determined by 
PCR in cord blood samples from newborns 
compared with 2% CMV infection identified by IgM 
assay and 99% IgG positivity; 100% IgG positivity 
and 3% IgM positivity in their mothers as tested by 
ELISA. 
The seroprevalence of CMV IgG antibody in 
pregnant women (100%) and the frequency of 
maternal infection (3%) obtained in this study is 
similar to the previous study in Iran (Tabatabaee 
and Tayyebi, 2009). They studied the prevalence 
of CMV antibody in 1472 pregnant women in the 
period of January, 2007 and July, 2007. The study 
reported a frequency of 97.69% for the 
seroprevalence of CMV IgG antibody and an 
active maternal CMV infection in 4.3% of the 
population. In our neighbour country, Turkey, the 
rate of CMV seropositivity was reported to be
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98.5% and the prevalence of maternal CMV infection was 
reported to be 1.2% (Satilmis et al., 2007). A study in 
Cuba (Kourí et al., 2010) screened 1131 pregnant 
women for the presence of CMV IgG and IgM in the 
period of 2007 to 2008. They found that most women 
(92.7%) were CMV IgG seropositive. Primary and active 
non-primary infection was reported in 20 (1.77%) and 
7(0.62%) of pregnant women. 
It was reported that the rate of CMV transmission in 
seropositive mothers undergoing recurrent infection and 
pregnant women with primary infection is 0.2 to 2% and 
20 to 40%, respectively (Boppana et al., 1999; Stagno 
and Whitley, 1985). As the seroconversion of pregnant 
women studied here was not previously monitored, the 
detection of CMV IgG does not lead to suspicion of 
primary infection. The study did not perform IgG avidity 
assay and the differentiation of primary and non primary 
infection is difficult. IgM assay was performed and 3% of 
pregnant women and 2% of cord serum of their newborns 
showed IgM positivity. Only two cord serum samples 
have detectable CMV IgM antibodies that is less than the 
IgM positivity in their corresponding mothers (n = 3). With 
the fact that IgM does not cross the placental barrier, 
these two babies may have intrauterine CMV infection. 
Detection of specific CMV IgM antibodies is a serological 
based method for diagnosis of primary CMV infection 
(Mace et al., 2004). However, different situations can be 
associated with the presence of IgM antibodies including 
the recurrent infection, the convalescent phase of a 
primary infection, the persistence of IgM or IgM 
crossreactivity due to herpes viruses other than CMV 
(Hodinka, 2003). Detection of IgM may be related to a 
primary infection occurring during pregnancy, although 
IgM can also be detected during reactivations. It has 
been previously proved that the main risk of intrauterine 
infection is associated with a primary infection during 
pregnancy (Fowler et al., 1992). However, with the fact 
that none of pregnant women in this study showed clear 
history of CMV infection during pregnancy and no IgM-
positive pregnant mother or positive baby gave 
symptoms and signs suggestive of CMV infections 
suggesting that intrauterine infection had occurred from a 
reactivated, asymptomatic infection with CMV. 
The study revealed a variation in ELISA and PCR 
results between mother sera and cord blood. Due to 
placental transfer of IgG, all mother's serum and cord 
serum samples revealed identical results for IgG 
antibodies against CMV. Paired mother sera/cord serum 
in 2 cases (case 2 and 4) showed IgM positivity in both 
sera and cord serum and DNA positivity in cord blood 
suggesting an active CMV infection in both mother and 
her baby. As the IgM does not cross the placental barrier, 
the IgM obtained in cord serum samples could originated 
from an active CMV infection occurred in babies during 
pregnancy or delivery. Detection of CMV DNA in cord 
blood by PCR may support this hypothesis. Case 3 had 
no detectable CMV IgM in sera and cord serum; however 
 
 
 
 
she had CMV DNA in cord blood suggesting an active 
CMV infection diagnosed only by PCR. Case 1 had no 
IgM in cord serum, but had IgM in sera and CMV DNA in 
cord blood suggesting an active CMV infection in both 
mother and baby. The most interesting finding in this 
study was that in ceases 1 and 3, PCR could detect CMV 
DNA in cord blood samples, while there was no 
detectable IgM in sera of mother (case 3) and cord serum 
(cases 1 and 3). Although, IgM assay is still considered 
as a reasonable tool for congenital CMV infection 
diagnosis (Melish and Hanshaw, 1973) it was reported 
that only 45 to 80% of babies congenitally infected with 
CMV could be recognized by detection of IgM (Griffiths et 
al., 1982). These data are further supported by the 
present study with the finding that in two cases of the 4 
congenital infected cases identified by PCR could IgM be 
found. The data show that the rate of congenital CMV 
infection detected by PCR (4%) is higher than that 
detected by IgM assay (2%). The utility of PCR in place 
of CMV IgM as a diagnostic method for congenital CMV 
infection is the most important finding of this study. PCR 
has been previously recognized as an important 
screening tool for congenital CMV infection. Also, to 
differentiate an active IgM case from non-active or false 
positive IgM case, PCR and virus detection has been 
suggested (Demler et al., 1998; Kourí et al., 2010). CMV 
DNA detected in specimens from 9 out of the 27 pregnant 
women by PCR. They suggested that mothers with active 
infection are at risk to have congenitally infected children. 
Also, no specific IgM could be in the fetal sera, the 
serological methods are unable to show this 
transmission. Thus, PCR method used here is the most 
suitable technique to screen CMV infection in newborns. 
Rapid screening and accurate diagnosis of active 
cytomegalovirus (CMV) infection are needed for 
complication prediction, treatment, infection control, and 
reducing the severity of the disease. PCR and an 
antibody assay are common methods for 
cytomegalovirus (CMV) infection detection, however, 
PCR may lead to more accurate diagnosis of maternal 
and congenital CMV infection. Future studies with larger 
number of samples and follow up the positive cases are 
required to determine the clinical impact of congenital 
CMV infections. 
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